/images/ppid_59c68470-image-17702050656233191.webp)
What is the story about?
Global Health Ltd, which operates hospitals under the Medanta brand, on Wednesday (February 4) reported a 33.6% year-on-year decline in net profit to ₹95 crore for the third quarter, compared with ₹143 crore in the same period last year.
Revenue rose 18.8% year-on-year to ₹1,121 crore from ₹943.3 crore. EBITDA fell 8.3% to ₹217.8 crore from ₹237.5 crore on a year-on-year basis. EBITDA margin stood at 19.4% in the quarter, compared with 25.2% in the corresponding period last year.
Global Health's board has approved the appointment of Malik Mohd. Ashhab as Senior Management Personnel of the company, designated as Head–Diagnostic Services.
Also Read: Budget 2026: Global Health, Aster DM rise up to 5% post FM's medical tourism push
The board also recommended certain proposals to shareholders for their consideration and approval. These include the re-appointment of Dr Ravi Gupta as an Independent Director for a second term of five consecutive years with effect from July 8, 2026.
In addition, the Board recommended the re-appointment of Rajan Bharti Mittal as an Independent Director for a second term of five consecutive years with effect from July 8, 2026. The Board further recommended the appointment of Shonan Purie Trehan as a Non-Executive Non-Independent Director of the company, liable to retire by rotation, with effect from March 13, 2026.
Shares of Global Health Ltd ended at ₹1,127.00, up by ₹13.00, or 1.17%, on the BSE.
Also Read: Global Health Q2 profit up 21% YoY; to expand Mumbai hospital to 750 beds
Revenue rose 18.8% year-on-year to ₹1,121 crore from ₹943.3 crore. EBITDA fell 8.3% to ₹217.8 crore from ₹237.5 crore on a year-on-year basis. EBITDA margin stood at 19.4% in the quarter, compared with 25.2% in the corresponding period last year.
Global Health's board has approved the appointment of Malik Mohd. Ashhab as Senior Management Personnel of the company, designated as Head–Diagnostic Services.
Also Read: Budget 2026: Global Health, Aster DM rise up to 5% post FM's medical tourism push
The board also recommended certain proposals to shareholders for their consideration and approval. These include the re-appointment of Dr Ravi Gupta as an Independent Director for a second term of five consecutive years with effect from July 8, 2026.
In addition, the Board recommended the re-appointment of Rajan Bharti Mittal as an Independent Director for a second term of five consecutive years with effect from July 8, 2026. The Board further recommended the appointment of Shonan Purie Trehan as a Non-Executive Non-Independent Director of the company, liable to retire by rotation, with effect from March 13, 2026.
Shares of Global Health Ltd ended at ₹1,127.00, up by ₹13.00, or 1.17%, on the BSE.
Also Read: Global Health Q2 profit up 21% YoY; to expand Mumbai hospital to 750 beds
